Showing 5311-5320 of 7714 results for "".
- Aveeno Opens Applications for 2022 Skin Health Startup Accelerator Pitch Competitionhttps://practicaldermatology.com/news/aveeno-opens-applications-for-2022-skin-health-startup-accelerator-pitch-competition/2461150/The Aveeno brand has announced its second year of the Aveeno Skin Health Start
- Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/long-term-complete-skin-clearance-data-for-bimekizumab-in-moderate-to-severe-plaque-psoriasis/2461137/UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, MA, including a late breaking oral platform presentation and 10 posters. The platform presentation details new
- RedDress Ships ActiGraft to Ukraine to Treat Civilian Casualtieshttps://practicaldermatology.com/news/reddress-ships-actigraft-to-ukraine-to-treat-civilian-casualties/2461133/
- Update: Skin Reactions to COVID-19 and Its Vaccineshttps://practicaldermatology.com/news/update-skin-reactions-to-covid-19-and-its-vaccines/2461125/
- New Guidelines from AAD Address Comorbidities of ADhttps://practicaldermatology.com/news/new-guidelines-from-aad-address-comorbidities-of-ad/2461060/New guidelines released this week by the American Academy of Dermatology (AAD)
- The National Eczema Association and Pediatric Dermatology Research Alliance Receive Collaborative Engagement Award from PCORIhttps://practicaldermatology.com/news/the-national-eczema-association-and-pediatric-dermatology-research-alliance-receive-collaborative-engagement-award-from-pcori/2461041/The
- DermBiont Acquires Chromadermhttps://practicaldermatology.com/news/dermbiont-acquires-chromaderm/2461017/
- FDA Fast Tracks Union Therapeutics' AD Candidatehttps://practicaldermatology.com/news/fda-fast-tracks-union-therapeutics-ad-candidate/2460978/The US Food and Drug Administration (FDA) has granted Fast Track designation to Union Therapeutics’ oral orismilast for the treatment of moderate to severe atopic dermatitis (AD). Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properti
- St. Ives Launches Social Media Contest to Help Reduce College Students' Financial and Skin Stresshttps://practicaldermatology.com/news/st-ives-launches-social-media-contest-to-help-reduce-college-students-financial-and-skin-stress/2460961/
- Arcutis Submits NDA for Topical Roflumilast Cream for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-submits-npa-for-topical-roflumilast-cream-for-plaque-psoriasis/2460942/